TIDMARIX 
 
Arix Bioscience plc 
 
     Imara files for proposed initial public offering in the United States 
 
LONDON, 17 February 2020: Arix Bioscience plc (LSE: ARIX) ("Arix Bioscience"), 
a global venture capital company focused on investing in and building 
breakthrough biotech companies, today announces that one of its portfolio 
companies, Imara Inc., ("Imara"), has filed a registration statement on Form 
S-1 with the U.S. Securities and Exchange Commission (the "SEC") for a proposed 
initial public offering ("IPO") in the United States of shares of its common 
stock. All shares to be sold in the offering will be offered by Imara. Imara 
has applied to list its common stock on the Nasdaq Global Market under the 
ticker symbol "IMRA". The offering is subject to market conditions, and there 
can be no assurance as to whether or when the offering may be completed, or as 
to the actual size or terms of the offering. A further announcement will be 
made in due course. 
 
A registration statement relating to these securities has been filed with the 
SEC but has not yet become effective. These securities may not be sold, nor may 
offers to buy be accepted, prior to the time the registration statement becomes 
effective. This announcement does not constitute an offer to sell or the 
solicitation of an offer to buy securities, and shall not constitute an offer, 
solicitation or sale in any jurisdiction in which such offer, solicitation or 
sale would be unlawful prior to registration or qualification under the 
securities laws of that jurisdiction. Any offers, solicitations or offers to 
buy, or any sales of securities will be made in accordance with the 
registration requirements of the Securities Act of 1933, as amended. 
 
The securities referred to in this release are to be offered only by means of a 
prospectus. When available, copies of the preliminary prospectus can be 
obtained from Morgan Stanley, 180 Varick Street, 2nd Floor, New York, New York 
10014, Attention: Prospectus Dept.; Citigroup, c/o Broadridge Financial 
Solutions, 1155 Long Island Avenue, Edgewood, New York, 11717 or by telephone 
at (800) 831-9146; or SVB Leerink, One Federal Street, 37th Floor, Boston, 
Massachusetts, 02110, Attention: Syndicate Department, by telephone at (800) 
808-7525, ext. 6132, or by email at syndicate@leerink.com. 
 
[ENDS] 
 
Enquiries 
 
For more information on Arix, please contact: 
 
Arix Bioscience plc 
Charlotte Parry, Head of Investor Relations 
+44 (0)20 7290 1072 
charlotte@arixbioscience.com 
 
Optimum Strategic Communications 
Mary Clark, Supriya Mathur 
+44 (0)20 3714 1787 
optimum.arix@optimumcomms.com 
 
This announcement includes information that is inside information as defined in 
Article 7 of the Market Abuse Regulation (EU) No.596/2014.The person 
responsible for arranging for the release of this announcement on behalf of 
Arix Bioscience plc is Robert Lyne, General Counsel. 
 
About Arix Bioscience plc 
 
Arix Bioscience plc is a global venture capital company focused on investing in 
and building breakthrough biotech companies around cutting edge advances in 
life sciences. 
 
We collaborate with exceptional entrepreneurs and provide the capital, 
expertise and global networks to help accelerate their ideas into important new 
treatments for patients. As a listed company, we are able to bring this 
exciting growth phase of our industry to a broader range of investors. 
 
Arix Bioscience plc is listed on the Main Market of the London Stock Exchange. 
For further information, please visit www.arixbioscience.com 
 
About Imara 
 
Imara Inc. is a clinical-stage biotechnology company dedicated to developing 
and commercializing novel therapeutics to treat patients suffering from rare 
inherited genetic disorders of hemoglobin, known as hemoglobinopathies. Imara 
is currently advancing IMR-687, a highly selective, potent small molecule 
inhibitor of PDE9 that is an oral, once-a-day, potentially disease-modifying 
treatment for sickle cell disease and beta-thalassemia. IMR-687 is being 
designed to have a multimodal mechanism of action that acts on red blood cells, 
white blood cells, adhesion mediators and other cell types. 
 
 
 
END

(END) Dow Jones Newswires

February 17, 2020 02:00 ET (07:00 GMT)

Grafico Azioni Arix Bioscience (LSE:ARIX)
Storico
Da Mar 2024 a Apr 2024 Clicca qui per i Grafici di Arix Bioscience
Grafico Azioni Arix Bioscience (LSE:ARIX)
Storico
Da Apr 2023 a Apr 2024 Clicca qui per i Grafici di Arix Bioscience